All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
The Lupus Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lupus Hub cannot guarantee the accuracy of translated content. The Lupus Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
Lupus nephritis (LN) is a serious complication of systemic lupus erythematosus, affecting approximately 40% of the patients. Furthermore, around 44% of the patients with class IV LN develop end-stage kidney disease within 15 years. Notably, 13%–37% of patients undergoing standard therapy (ST) for LN experience renal flare within 3–5 years, emphasizing the need for novel treatments to preserve kidney function.
The phase III, randomized, double-blind BLISS-LN study (NCT01639339) has demonstrated that the addition of belimumab to ST improves renal outcomes in patients with active LN. However, data on its efficacy at different disease stages or with different induction regimens is limited. Here, we present a visual abstract summarizing post-hoc analyses from the BLISS-LN trial in patients with newly diagnosed or relapsed LN, including those with or without glucocorticoid pulses at induction.1
Subscribe to get the best content related to lupus delivered to your inbox